Bioxytran (BIXT) Accumulated Expenses (2011 - 2026)
Bioxytran (BIXT) posted Accumulated Expenses of $4805.0 for Q1 2026, down 89.03% sequentially from $43787.0 in Q4 2025, and down 37.46% YoY from $7683.0 in Q1 2025.
Bioxytran (BIXT) Accumulated Expenses (2011 - 2026) Analysis & Trends
Bioxytran has reported Accumulated Expenses for 14 years, with the latest figure at $4805.0 in Q1 2026.
- Quarterly Accumulated Expenses fell 37.46% year-over-year to $4805.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4805.0 (down 37.46% YoY) and the FY2025 annual result came in at $43787.0, up 266.6% from the prior year.
- Accumulated Expenses retreated to $4805.0 in Q1 2026 per BIXT's latest filing, from $43787.0 in the prior quarter.
- Over five years, Accumulated Expenses peaked at $727110.0 in Q2 2025 and troughed at $657.0 in Q1 2024.
- A 5-year average of $96940.5 and a median of $27065.0 in 2024 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2025: Accumulated Expenses tumbled 98.57% in 2024, then surged 27010.74% in 2025.
- Over 5 years, Accumulated Expenses stood at $134581.0 in 2022, then soared by 66.26% to $223759.0 in 2023, then slumped by 94.66% to $11944.0 in 2024, then soared by 266.6% to $43787.0 in 2025, then slumped by 89.03% to $4805.0 in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $4805.0, $43787.0, and $42186.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Bioxytran | 2.47 Mn | 2.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4,805.00 |
| Dec 31, 2025 | 43,787.00 |
| Sep 30, 2025 | 42,186.00 |
| Jun 30, 2025 | 727,110.00 |
| Mar 31, 2025 | 7,683.00 |
| Dec 31, 2024 | 11,944.00 |
| Sep 30, 2024 | 2,934.00 |
| Jun 30, 2024 | 2,682.00 |
| Mar 31, 2024 | 657.00 |
| Dec 31, 2023 | 223,759.00 |
| Sep 30, 2023 | 185,967.00 |
| Jun 30, 2023 | 1,546.00 |
| Mar 31, 2023 | 45,887.00 |
| Dec 31, 2022 | 134,581.00 |
| Sep 30, 2022 | 113,210.00 |
| Jun 30, 2022 | 2,310.00 |
| Dec 31, 2021 | 85,685.00 |
| Jun 30, 2018 | 28,476.00 |
| Mar 31, 2018 | 26,526.00 |
| Dec 31, 2017 | 24,576.00 |